Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Psychostimulant abuse is a serious social and health problem, for which no effective treatments currently exist. A number of review articles have described predominantly 'clinic'-based pharmacotherapies for the treatment of psychostimulant addiction, but none have yet been shown to be definitively effective for use in humans. In the present article, we review various 'hypothesis'- or 'mechanism'-based pharmacological agents that have been studied at the preclinical level and evaluate their potential use in the treatment of psychostimulant addiction in humans. These compounds target brain neurotransmitter or neuromodulator systems, including dopamine (DA), gamma-aminobutyric acid (GABA), endocannabinoid, glutamate, opioid and serotonin, which have been shown to be critically involved in drug reward and addiction. For drugs in each category, we first briefly review the role of each neurotransmitter system in psychostimulant actions, and then discuss the mechanistic rationale for each drug's potential anti-addiction efficacy, major findings with each drug in animal models of psychostimulant addiction, abuse liability and potential problems, and future research directions. We conclude that hypothesis-based medication development strategies could significantly promote medication discovery for the effective treatment of psychostimulant addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“Two major types of cannabinoid receptors, CB1 and CB2, have been cloned [200, 201].”
BackgroundCellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Childress, A.-R., Jayne, M., Ma, Y., & Wong, C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-06.2006 · Cited by 1,164 · cited 2×
“Given that chronic cocaine appears to produce a reduction in basal mesolimbic DA transmision in both humans and experimental animals after withdrawal or abstinence [23, 43-46], the l-THP-induced modest augmentation of extracellular DA may also contribute to its therapeutic anti-cocaine actions by correcting the hypofu…”
BackgroundRegulation of Neurotransmitter Release by Metabotropic Glutamate Receptors
Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883
Addictive Drugs and Brain Stimulation Reward
Wise, R. A. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.001535 · Cited by 792
Thomas, M. J., Beurrier, C., Bonci, A., & Malenka, R. C. (2001) · Nature Neuroscience · doi:10.1038/nn757 · Cited by 629
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“Agonist substitution hypothesis: Agonist substitution as a pharmacotherapy for psychostimulant addiction is based on, first, the success of methadone in the treatment of opiate dependence and the nicotine patch for smoking cessation; second, the finding that the speed with which addictive drugs enter the brain and ele…”
BackgroundGoodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Cited by
Addiction and Brain Reward and Antireward Pathways
Gardner, E. L. (2011) · Advances in Psychosomatic Medicine · doi:10.1159/000324065 · Cited by 417
Self-citationZhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
“Given that midbrain DA neurons of the ventral tegmental area (VTA) play an important role in mediating the reinforcing and addictive effects of drugs of abuse (28, 29), we hypothesized that brain CB2Rs, similar to other G protein-coupled receptors, are expressed in VTADA neurons, where they modulate DA neuronal functi…”
BackgroundSelf-citationReward circuitry function in autism during face anticipation and outcomes
Dichter, G. S., Richey, J. A., Rittenberg, A. M., Sabatino, A., & Bodfish, J. W. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1221-1 · Cited by 222
The oxytocin receptor impairs ethanol reward in mice
Bahi, A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.046 · Cited by 55
Metadata
- Authors
- Xi, Z.-X., & Gardner, E.
- Venue
- Current Drug Abuse Reviewse
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 1
- Issue
- 3
- Pages
- 303-327
- ISSN
- 1874-4737 (ISSN-L)
- OpenAlex
- W2060937634
- Cited by
- 70
- References
- 22
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction. https://app.cochat.ai/papers/10.2174/1874473710801030303
- The paper
- Xi, Z.-X., & Gardner, E. (2008). Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction. Current Drug Abuse Reviewse. https://doi.org/10.2174/1874473710801030303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.